Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Islet Studies

Mitochondrial Reactive Oxygen Species Are Obligatory Signals for Glucose-Induced Insulin Secretion

  1. Corinne Leloup1,
  2. Cécile Tourrel-Cuzin2,
  3. Christophe Magnan2,
  4. Melis Karaca2,
  5. Julien Castel2,
  6. Lionel Carneiro1,
  7. Anne-Laure Colombani1,
  8. Alain Ktorza2,
  9. Louis Casteilla1 and
  10. Luc Pénicaud1
  1. 1Department of Metabolism, Plasticity, and Mitochondria, Unité Mixte de Recherche 5241, Centre National de la Recherche Scientifique-Université Paul Sabatier, Institut Fédératif de Recherche 31, Institut Fédératif de Recherche 109, Toulouse, France
  2. 2Unité Mixte de Recherche 7059, Centre National de la Recherche Scientifique, Paris, France
  1. Corresponding author: Corinne Leloup, coleloup{at}toulouse.inserm.fr
Diabetes 2009 Mar; 58(3): 673-681. https://doi.org/10.2337/db07-1056
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Glucose induces ROS production in isolated rat islets. A: Glucose challenge (16.7 mmol/l) in a 30-min static incubation triggered a threefold increase in ROS fluorescence. B: ROS production was accompanied by a classical GSIS. Quenching ROS by trolox completely blunted GSIS. A and B: Three independent experiments, n = 6 per group; ***P < 0.001, glucose 5.5 vs. 16.7 mmol/l; ###P < 0.001, glucose 16.7 vs. 16.7 mmol/l+trolox. C: Dynamic experiments using perifusion demonstrating the antioxidant-induced reduction of GSIS. Three independent experiments, P < 0.001 between vehicle and treated groups and between 16.7 mmol/l glucose vs. 16.7 mmol/l glucose + trolox. D and E: Modulation of glucose-induced ROS production and GSIS by gradual antioxidant doses. Three independent experiments, n = 6 per group; **P < 0.01 or ***P < 0.001, 16.7 mmol/l glucose + 1 nmol/l trolox vs. 16.7 mmol/l glucose + 1 μmol/l trolox; ##P < 0.01 or ### P < 0.001, 16.7 mmol/l glucose + 1 μmol/l trolox vs. 16.7 mmol/l glucose + 1 mmol/l trolox. F: In these conditions, the regression linking ROS production to insulin secretion (r = 0.899) was highly significant P < 0.001. A.U., arbitrary unit.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    ROS kinetics paralleled insulin secretion in GSIS. A: Intracellular H2O2 production measured with H2-DCFDA probe. Freshly isolated islets on 5.5 mmol/l glucose before time 0 were treated with 16.7 mmol/l glucose the lasting 30 min. ROS production appeared maximally and reached a plateau at 5 min. B: Insulin secretion immediately followed this ROS production and shared a similar profile.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    mROS mimic GSIS in β-cells islets. A: Effect of treatments on intracellular H2O2 production measured with H2-DCFDA probe. Treatments were as follows: 100 μmol/l rotenone or 20 μmol/l antimycin, inhibitors of complexes I and III, respectively, added to the 30-min static incubation in 5.5 mmol/l glucose; 1 mmol/l trolox or 1 mmol/l glutathione reduced ethyl ester (GE) cotreatment with 16.7 mmol/l glucose or rotenone (rot) or antimycin (ant); 16.7 mmol/l glucose coadministrated with the uncoupler CCCP. C: Insulin release measurement in the same conditions. A and C: Three independent experiments, n = 6 per group. ***P < 0.001, glucose 5.5 vs. 16.7 mmol/l, vs. 5.5 mmol/l glucose + rot or 5.5 mmol/l glucose + ant; ###P < 0.001, 5.5 mmol/l glucose + rot vs. 5.5 mmol/l glucose + rot + trolox or glutathione ethyl ester (GE); §§§P < 0.001, 5.5 mmol/l glucose + ant vs. 5.5 mmol/l glucose + ant + trolox or glutathione ethyl ester (GE); ‡‡‡P < 0.001, 16.7 mmol/l glucose vs. 16.7 mmol/l glucose + CCCP. E: Dynamic insulin secretion using perifusion model under rotenone alone or in presence of the antioxidant trolox. Three independent experiments, with one perifused column per case, P < 0.001 between vehicle and treated groups and between rotenone vs. rotenone + trolox. B and D: Modulation of rotenone-induced ROS production and GSIS by gradual antioxidant doses. ROS-dependent response might be established with insulin secretion in static incubation. Three independent experiments, n = 6 per group; ***P < 0.001, rotenone + 1 nmol/l trolox vs. rotenone + 1 μmol/l trolox; ###P < 0.001, rotenone + 1 μmol/l trolox vs. rotenone + 1 mmol/l trolox. F: In these conditions, the regression linking ROS production to insulin secretion (r = 0.883) was highly significant P < 0.001. ⋄, vehicle; ♦, glucose 16.7 mM; ▴, rotenone; □, rotenone + trolox.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    NADH and ATP increases are not necessary for mROS-induced insulin secretion. Ratio of either ROS production as measured with H2-DCFDA (A), NADH (B), insulin secretion (C), or ATP (D) compared with basal condition (5.5 mmol/l glucose) in three independent experiments, n = 4 per group. A and C: Static islet incubation for 30 min in 16.7 mmol/l glucose cotreated with trolox abolished ROS production and blunted insulin secretion; ***P < 0.001, glucose 16.7 vs. 5.5 mmol/l; ###P < 0.001, 16.7 mmol/l glucose + trolox vs. 16.7 mmol/l glucose alone. B and D: Both NADH and ATP were increased, although insulin secretion was abolished when ROS were blunted; *P < 0.05 or **P < 0.001, 16.7 mmol/l glucose + trolox vs. 16.7 mmol/l glucose alone. Conversely, 100 μmol/l rotenone (rot) stimulated ROS production and insulin secretion (A and C), independently of NADH or ATP (B and D), which were unchanged compared with controls. ***P < 0.001, 5.5 mmol/l glucose + rotenone vs. 5.5 mmol/l glucose; §§§P < 0.001 or §P < 0.05, 5.5 mmol/l glucose + rotenone vs. 5.5 mmol/l glucose + rotenone + trolox.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Intracellular calcium profiles after glucose, mitochondrial blocker, or KCl treatment. A: Intracellular calcium expressed as the ratio of fura-2 probe fluorescence (340 nm/380 nm) from basal conditions (5 mmol/l glucose) to 16.7 mmol/l glucose. Addition of the antioxidant trolox significantly reverses the [Ca2+]i mobilization classically observed with glucose concentration increase. C: The experiment was repeated except that instead of raising glucose, 100 μmol/l rotenone was added to islets. Addition of rotenone first led to a transient fall in [Ca2+]i the first 8 min, followed by a large and sustained increase. B: Investigation of calcium origin using 1 mmol/l EGTA after removal of Ca2+ from the extracellular bath solution. Increasing the glucose concentration or adding rotenone first triggered a typical biphasic response, and the presence of EGTA resulted in a profound decrease of fluorescence fura-2 ratio 340:380 for both glucose and rotenone. D: Investigation of calcium origin using 1 μmol/l thapsigargin in islets treated with either 16.7 mmol/l glucose or 100 μmol/l rotenone did not suppress the massive increase of [Ca2+]i. The experiment shown is representative of three (glucose and mitochondrial blockers) or two (KCl) with similar results.

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Islet preservation under the different mitochondrial treatments. A: To exclude a damaging and nonspecific oxidative stress, lipid peroxidation was evaluated. Hydroperoxides were evaluated on islets treated in static incubation for 30 min with 100 μmol/l rotenone, 1 μmol/l CCCP, or 20 μmol/l antimycine compared with basal conditions, 5.5 mmol/l glucose. No difference in these groups compared with glucose was observed. B: Insulin resecretion after the 100 μmol/l rotenone or 20 μmol/l antimycin treatment consisted to expose islets to GSIS after they were stimulated with the mitochondrial blockers for 30 min and insulin was measured in the milieu. They were replaced in basal glucose (5.5 mmol/l) for 30 min further, and insulin was reevaluated before a GSIS was done. In these conditions, insulin release was absent in the milieu in basal conditions, and the ability of glucose to restimulate insulin secretion was totally maintained after the pharmacological treatments. Three independent experiments, n = 6; ***P < 0.001, glucose 16.7 vs. 5.5 mmol/l. Bars represent SE in all figures. They were not represented for perifused-islet experiments. Ant, antimycin; rot, rotenone.

PreviousNext
Back to top

In this Issue

March 2009, 58(3)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mitochondrial Reactive Oxygen Species Are Obligatory Signals for Glucose-Induced Insulin Secretion
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mitochondrial Reactive Oxygen Species Are Obligatory Signals for Glucose-Induced Insulin Secretion
Corinne Leloup, Cécile Tourrel-Cuzin, Christophe Magnan, Melis Karaca, Julien Castel, Lionel Carneiro, Anne-Laure Colombani, Alain Ktorza, Louis Casteilla, Luc Pénicaud
Diabetes Mar 2009, 58 (3) 673-681; DOI: 10.2337/db07-1056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Mitochondrial Reactive Oxygen Species Are Obligatory Signals for Glucose-Induced Insulin Secretion
Corinne Leloup, Cécile Tourrel-Cuzin, Christophe Magnan, Melis Karaca, Julien Castel, Lionel Carneiro, Anne-Laure Colombani, Alain Ktorza, Louis Casteilla, Luc Pénicaud
Diabetes Mar 2009, 58 (3) 673-681; DOI: 10.2337/db07-1056
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
  • Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with KATP Channels
  • Pancreatic β-Cell–Specific Deletion of VPS41 Causes Diabetes Due to Defects in Insulin Secretion
Show more Islet Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.